Dr. Matthias Magoola, founder and Managing Director of Dei Biopharma Ltd, has received the prestigious Best Researcher Award at the International Molecular Biologist Awards for his pioneering contributions to vaccines research and drug development.
The annual accolade honours a scientist whose molecular discoveries have significantly advanced human health.
Dr. Magoola’s work was recognised for its innovative focus on messenger RNA (mRNA) technology as a cost-effective solution for producing therapeutic drugs and protein vaccines.
Dr. Magoola’s award-winning study, titled “Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery—A Humanitarian Cause”, was published in the International Journal of Molecular Sciences.
The paper explores how mRNA technology offers a more efficient and affordable method for producing therapeutic proteins compared to traditional recombinant technology.
“The validation of in vivo messenger RNA (mRNA) technology has been accomplished for COVID-19 vaccines,” the study notes, highlighting ribosomes as natural bioreactors that deliver these proteins at minimal cost.
Commenting on the recognition, Dr. Magoola emphasised the humanitarian impact of reducing drug costs.
“The cost of therapeutic drugs and protein vaccines remains prohibitively high, making them inaccessible to over 6.5 billion people globally,” he said. “This research provides a pathway to affordable drug production, especially for developing nations.”
Dr. Magoola expressed hope that his findings would empower developing countries to manufacture their own therapeutic drugs.
He credited his team at Dei Biopharma for their dedication, stating, “We are grateful to the Molecular Biologist Awards for recognising our work. This is a testament to the sleepless nights and commitment of the Dei Biopharma team.”
This recognition comes on the heels of Dr. Magoola earning a Doctorate of Philosophy (PhD) from the European International University in France.
He also authored another study, “Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease”, published in Pharmaceuticals, a peer-reviewed journal.
Dr. Magoola, a graduate of Makerere University with a Bachelor of Science in Industrial Chemistry, has spearheaded Dei Biopharma’s ambitious projects, including Uganda’s flagship biological drug and vaccine manufacturing facility in Mattuga, Wakiso District.
Among his notable achievements is the development of the Dei Anti-Malarial drug, hailed as the most effective anti-malarial treatment to date.
The drug, patented in the United States, represents a groundbreaking advancement in malaria treatment.
He also developed a COVID-19 vaccine using mRNA technology, which is currently stored in a U.S. cell bank, and holds over 100 patents for treatments and vaccines targeting diseases such as cancer, HIV, malaria, tuberculosis, diabetes, and Alzheimer’s.
One of Dr. Magoola’s pioneering patents involves the use of mRNA to produce Darbepoetin, a therapeutic protein for acute kidney failure and cancer treatment.
The U.S. Food and Drug Administration (FDA) has provided positive feedback on this novel product, enabling its continued development. Additionally, Dr. Magoola has sought FDA approval for a vaccine targeting neurodegenerative disorders, including Alzheimer’s disease.
Dr. Magoola’s contributions have earned him membership in Sigma Xi, an elite scientific society that counts Albert Einstein and Linus Pauling among its members.
He has also been named by the Silicon Valley Review as one of the pharmaceutical CEOs to watch in 2025.
This international recognition cements Dr. Magoola’s status as a leading innovator in molecular biology and pharmaceutical research, with his work poised to transform global healthcare.
